Table I.
4 Weeks | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
Absolute # (compared to 4NQO Control) | Tconv | Treg | Activated Tconv | Th1/Tc1 | Th17/Tc17 | Th2 | ||||
CD4+ Foxp3− | CD8+ Foxp3− | CD4+ Foxp3+ | CD25+ CD4 Tconv | CD44hi CD4 Tconv | CD4+ IFN-γ+ | CD8+ IFN-γ+ | CD4+ IL-17A+ | CD8+ IL-17A+ | CD4+ IL-10+ | |
DCnt | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |
DCpm |
8 Weeks | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Absolute # (compared to 4NQO Control) | Tconv | Treg | Activated Tconv | Tc1 | Th17/Tc17 | Th2 | |||||
CD8+ Foxp3− | CD4+ Foxp3+ | CD8+ Foxp3+ | CD25+ CD8 Tconv | CD44hi CD4 Tconv | CD44hi CD8 Tconv | CD8+ IFN-γ+ | CD4+ IL-17A+ | CD8+ IL-17A+ | CD4+ IL-4+ | CD4+ IL-13+ | |
DCnt | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ||
DCpm | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |